Navigation Links
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting

of Days 2-5, and during the overall period of Days 1-5. On Day 1, 100% of patients had no emesis and at least 95% of patients had no emetic episodes in the delayed and overall time periods. A complete response was demonstrated in 75% of patients on Day 1 and in 67% of patients in the delayed time period. Based on VAS, the majority of patients had no significant nausea in the acute, delayed or overall phases. The most commonly observed adverse events were headache and fatigue.

Phase 3 Results of Aloxi in Pediatric Patients

The results of a phase 3, multicenter, randomized, double-blind study to assess the safety, efficacy and pharmacokinetics of single intravenous doses of Aloxi in pediatric patients were presented in a poster session on Sunday, June 3, 2007. Sixty patients (2-17 years of age) were randomized to receive either 3 mcg/kg or 10 mcg/kg with a maximum total dose of 0.25 mg and 0.75mg, respectively, prior to moderately (n=21) or highly (n=39) emetogenic chemotherapy. Twelve additional patients, age 28 days-23 months, were studied in open-label design at the same doses. The majority of patients had received previous chemotherapy. Day 1 complete response (CR: no emetic episodes and no rescue medication) rates of 37.1% (CI, 22.0-55.1%) and 54.1% (CI, 37.1-70.2%) were reported in the 3 mcg/kg (n=35) and 10 mcg/kg (n=37) groups, respectively. The percentage of patients who were emesis-free was numerically higher in the 10 mcg/kg group; however, as with CR, these differences were primarily seen in children less than 2 years. A numerically higher proportion of patients (aged 6-17 years) with no nausea was also observed in the 10 mcg/kg group. Both doses showed a similar time to treatment failure (time to first emetic episode and/or first administration of rescue medication). The pharmacokinetic data show that total body clearance and volume of distribution of Aloxi increased with age-related body weight, as expected. The long half-life (21-37 hours
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
8. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
9. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
10. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
Post Your Comments:
(Date:8/22/2014)... 22, 2014  Landauer, Inc. (NYSE: LDR ... measurement and monitoring, outsourced medical physics services and high ... E. Saxelby , its President and Chief Executive Officer, ... Officer and as a member of the Board of ... be replaced on an interim basis by Michael ...
(Date:8/21/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a multivariate ... has appointed Holly B. Bauzon as Vice ... Bauzon has a proven track record in both increasing ... companies. She has more than 20 years of healthcare ... the position of Director, Lab Services Sales and Managed ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is ... introduction of the first-of-its-kind comic book available in ... has been designed specifically to educate children and their parents ... Canada affecting more than 300,000 Canadians. Eisai is ... care (hhc) , in which the patient is central – ...
Breaking Medicine Technology:Landauer, Inc. Announces Executive Management Change 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: ... Cephalon, Inc. (NASDAQ: CEPH): In a letter ... stated that it "is presently undertaking a review of ... is focused on maximizing Cephalon shareholder value."  We know ...
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... to discuss first quarter 2011 financial results, as well as ... at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time; 2:00 ... ended March 31, 2011 will be released earlier that day. ...
Cached Medicine Technology:Valeant Pharmaceuticals Responds to Cephalon Board's Letter 2Valeant Pharmaceuticals Responds to Cephalon Board's Letter 3Valeant Pharmaceuticals Responds to Cephalon Board's Letter 4Onyx Pharmaceuticals Announces First Quarter 2011 Financial Results Teleconference and Webcast 2
(Date:8/22/2014)... (PRWEB) August 22, 2014 Dayton Children's Hospital ... tower as part of a $141 million campus renewal. ... care tower were unveiled to the public. , The ... plan that will create a campus that meets the needs ... These new care spaces will embody Dayton Children’s unique patient ...
(Date:8/22/2014)... artery stenting to open blockages in the kidney ... excluded from modern clinical trials, according to new ... Catheterization and Cardiovascular Interventions today by the ... University Hospitals Case Medical Center,s Sahil Parikh, MD, ... Medicine, Case Western Reserve University School of Medicine ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Menstrual leaks ... inventor from Sunrise, Fla., decided that there needed to ... Easy to use and producible in design variations, the ... caused by leaks, which avoids embarrassment and promotes peace ... conventional sanitary pads. , The original design was submitted ...
(Date:8/22/2014)... 2014 (HealthDay News) -- People who use reduced-nicotine cigarettes ... levels of nicotine, according to a new study. ... other smokers, the researchers say. The month-long study ... smoked regular cigarettes with nicotine emission levels of 1.2 ... switched to reduced-nicotine cigarettes for the next three weeks. ...
(Date:8/22/2014)... 2014 (HealthDay News) -- Many children get anxious or ... there are a number of ways that parents can ... suggests. The first step is to explain to ... protect their health, said Rita John, director of the ... School of Nursing in New York City. "Children ...
Breaking Medicine News(10 mins):Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3Health News:Low-Nicotine Cigarettes May Not Lead to More Smoking 2Health News:Simple Steps Make Shots Less Scary for Kids, Nurse Says 2
... (HealthDay News) -- Researchers report that DNA analysis has led ... disease, along with its genetic cause. As described in ... of Medicine , the debilitating, painful and progressive disease is ... and feet of patients, and in the vascular network below ...
... Feb. 2 (HealthDay News) -- In families where dads ... be more supportive of each other,s parenting styles. ... may have more disagreements than couples in which mom ... State University study included 112 Midwestern couples with a ...
... WEDNESDAY, Feb 2 (HealthDay News) -- Victorious wrestlers have ... than their vanquished opponents, a new study finds. ... elite collegiate wrestling team before and after their matches. ... other hormones. In all the wrestlers, testosterone levels ...
... in the United States, account for a disproportionate share ... more than half of clinical trials exclude people based ... new study by Robert Wood Johnson Foundation (RWJF) Clinical ... findings are concerning because it means that doctors cannot ...
... FDA-approved hypertension medication may improve the results of ... report in the early edition of Proceedings ... General Hospital (MGH) investigators describe experiments showing that ... of collagen fibers that characterizes most solid tumors, ...
... available in French . Montreal, February 2, ... (LGB) are at far higher risk for severe mental health ... suggests that the stress of being rejected or victimized because ... and bisexuals. Recently published as a doctoral thesis ...
Cached Medicine News:Health News:Scientists Discover Rare Vascular Disease 2Health News:Parents Have Stronger Relationship When Dad Plays With Kids 2Health News:Older adults often excluded from clinical trials 2Health News:Generic drug may improve the effectiveness of cancer nanotherapies 2Health News:Physiological impacts of homophobia 2Health News:Physiological impacts of homophobia 3
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
... The CSV-1000S test face is widely used ... evaluation. This test presents standard visual acuity from ... (6 and 12 cycles/degree) and a real-world driver's ... cataract documentation as it provides a standard acuity ...
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
... those involved with healthcare decisions to keep ... evidence in their field of interest - ... as the volume of evidence increases. Cochrane ... best single source available for continually updated ...
Medicine Products: